B-hPD-1 plus/hPD-L1 mice
| Strain Name | C57BL/6N-Pdcd1tm3(PDCD1)BcgenCd274tm1(CD274)Bcgen/Bcgen | Common Name | B-hPD-1 plus/hPD-L1 mice |
| Background | C57BL/6 | Catalog number | 112550 |
|
Related Genes |
CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1; B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, hPD-L1 |
||
模型验证
In vivo efficacy of anti-human PD-1 antibody
Percentages of leukocytes in CD45+ TILs
Percentages of leukocyte subpopulations in TILs
Percentages of hPD-1+ cells in TILs
Percentages of hPD-L1+ cells in tumor tissue
Percentages of activated cells
Expression levels of hPD-1 on TILs
Expression level of hPD-L1 on TILs
Antitumor activity of anti-human PD-1 antibodies in B-hPD-1 plus/PD-L1 mice. Anti-human PD-1 antibody pembrolizumab (in house) and nivolumab (in house) inhibited the growth of B-hPD-L1 MC38 plus in B-hPD-1 plus/PD-L1 mice. Murine colon cancer B-hPD-L1 MC38 plus cells were subcutaneously implanted into B-hPD-1 plus/PD-L1 mice (female, 8-week-old, n=6). Mice were grouped when tumor volume reached approximately 80-120 mm3, at which time they were treated with anti-human PD-1 antibodies with doses indicated in panel. (A) Tumor volume and body weight of mice treated with pembrolizumab. (B) Tumor volume and body weight of mice treated with nivolumab. Results showed that pembrolizumab and nivolumab were both efficacious in controlling tumor growth in B-hPD-1 plus/PD-L1 mice. The tumor inhibitory effects were dose-dependent. The results demonstrate that the B-hPD-1 plus/PD-L1 mice provide a powerful preclinical model for in vivo evaluation of anti-human PD-1 antibodies. Values are expressed as mean ± SEM.
Flow cytometry analysis of tumor infiltrating lymphocytes (TILs). Tumor cells were harvested at the endpoint of experiment (n=3). Flow cytometry analysis of the lymphocytes were performed to assess cell proportion changes in anti-human PD-1 antibodies (in house) treated groups compared to the group treated with isotype antibody. Values are expressed as mean ± SEM.
Flow cytometry analysis of tumor infiltrating lymphocytes (TILs). Tumor cells were harvested at the endpoint of experiment (n=3). Flow cytometry analysis of the lymphocytes were performed to assess cell proportion changes in anti-human PD-1 antibodies (in house) treated groups compared to the group treated with isotype antibody. Values are expressed as mean ± SEM.
Flow cytometry analysis of tumor infiltrating lymphocytes (TILs). Tumor cells were harvested at the endpoint of experiment (n=3). Flow cytometry analysis of the lymphocytes were performed to assess cell proportion changes in anti-human PD-1 antibodies (in house) treated groups compared to the group treated with isotype antibody. Values are expressed as mean ± SEM.
Flow cytometry analysis of tumor infiltrating lymphocytes (TILs). Tumor cells were harvested at the endpoint of experiment (n=3). Flow cytometry analysis of the lymphocytes were performed to assess cell proportion changes in anti-human PD-1 antibodies (in house) treated groups compared to the group treated with isotype antibody. Values are expressed as mean ± SEM.
Flow cytometry analysis of tumor infiltrating lymphocytes (TILs). Tumor cells were harvested at the endpoint of experiment (n=3). Flow cytometry analysis of the lymphocytes were performed to assess cell proportion changes in anti-human PD-1 antibodies (in house) treated groups compared to the group treated with isotype antibody. Values are expressed as mean ± SEM.
Flow cytometry analysis of tumor infiltrating lymphocytes (TILs). Tumor cells were harvested at the endpoint of experiment (n=3). Flow cytometry analysis of the lymphocytes were performed to assess cell proportion changes in anti-human PD-1 antibodies (in house) treated groups compared to the group treated with isotype antibody. Values are expressed as mean ± SEM.
Flow cytometry analysis of tumor infiltrating lymphocytes (TILs). Tumor cells were harvested at the endpoint of experiment (n=3). Flow cytometry analysis of the lymphocytes were performed to assess cell proportion changes in anti-human PD-1 antibodies (in house) treated groups compared to the group treated with isotype antibody. Values are expressed as mean ± SEM.
010-56967680
info@bbctg.com.cn
Copyright © 2024 百奥赛图江苏基因生物技术有限公司. All Rights Reserved
备案号： 苏ICP备2021053911号-1
苏公网安备：32068402320845号
网站建设：北京分形科技
苏公网安备：32068402320845号
网站建设：北京分形科技